{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T18:09:12Z","timestamp":1792346952030,"version":"4.4.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Child Adolesc. Psychiatry"],"abstract":"<jats:sec><jats:title\/><jats:p>The early onset, high prevalence, persistence and comorbidity of developmental disorders make affective dysregulation (AD) in childhood and adolescence one of the conditions with the greatest psychosocial burden and economic impact on society. Despite ongoing research, there remains a substantial need to optimize individualized treatment strategies to improve treatment outcomes and alleviate subjective distress and economic costs. The objective of this study is to investigate psychopathological markers of AD in children and adolescents with attention-deficit\/hyperactivity disorder (ADHD) treated with the drug guanfacine as part of routine clinical care. These ADHD patients typically have not responded adequately to methylphenidate or other stimulant treatment. This study will employ a multicenter, single-arm design to evaluate the effects of guanfacine on AD symptoms in <jats:italic>n<\/jats:italic>\u2009=\u200940 patients of children and adolescents receiving regular ADHD treatment. The findings of this study are expected to address the hypothesis that guanfacine provides beneficial effects on symptoms of AD in addition to its effects on symptoms of ADHD.\n<\/jats:p><\/jats:sec><jats:sec><jats:title>Public clinical trial registry<\/jats:title><jats:p>Affective Dysregulation (AD) in Children With ADHD Treated by Guanfacin, <jats:uri>ClinicalTrials.gov<\/jats:uri> ID NCT04016207.<\/jats:p><\/jats:sec>","DOI":"10.3389\/frcha.2025.1547672","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T06:52:47Z","timestamp":1743144767000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of affective dysregulation in ADHD with guanfacine: study protocol"],"prefix":"10.3389","volume":"4","author":[{"given":"Johanna","family":"Waltereit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Uhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Tarassidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Preuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veit","family":"Roessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Waltereit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00787-019-01438-x","article-title":"Affective dysregulation: a transdiagnostic research concept between ADHD, aggressive behavior conditions and borderline personality traits","volume":"28","author":"Waltereit","year":"2019","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1017\/S0954579413000722","article-title":"The developmental psychopathology of irritability","volume":"25","author":"Leibenluft","year":"2013","journal-title":"Dev Psychopathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1176\/appi.ajp.2013.13070966","article-title":"Emotion dysregulation in attention deficit hyperactivity disorder","volume":"171","author":"Shaw","year":"2014","journal-title":"Am J Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1017\/S0033291708004662","article-title":"Mood lability and psychopathology in youth","volume":"39","author":"Stringaris","year":"2009","journal-title":"Psychol Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1176\/appi.ajp.2012.12010132","article-title":"Prevalence, comorbidity, and correlates of DSM-5 proposed disruptive mood dysregulation disorder","volume":"170","author":"Copeland","year":"2013","journal-title":"Am J Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1469-7610.2007.01733.x","article-title":"Lifetime prevalence, correlates, and persistence of oppositional defiant disorder: results from the national comorbidity survey replication","volume":"48","author":"Nock","year":"2007","journal-title":"J Child Psychol Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1377\/hlthaff.23.5.155","article-title":"Childhood origins of adult health: a basis for life-course health policy","volume":"23","author":"Forrest","year":"2004","journal-title":"Health Affairs (Project Hope)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1176\/appi.ajp.2010.09091379","article-title":"Research domain criteria (RDoC): toward a new classification framework for research on mental disorders","volume":"167","author":"Insel","year":"2010","journal-title":"Am J Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"212286","DOI":"10.7573\/dic.212286","article-title":"Alpha-2 receptor agonists for the treatment of posttraumatic stress disorder","volume":"4","author":"Belkin","year":"2015","journal-title":"Drugs Context"},{"key":"B10","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1089\/cap.2013.0028","article-title":"A review of the rationale and clinical utilization of alpha2-adrenoceptor agonists for the treatment of attention-deficit\/hyperactivity and related disorders","volume":"23","author":"Sallee","year":"2013","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1378\/chest.83.2.340","article-title":"Pharmacology and characterization of central alpha-adrenoceptors involved in the effect of centrally acting antihypertensive drugs","volume":"83","author":"van Zwieten","year":"1983","journal-title":"Chest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1101\/lm.298006","article-title":"Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals","volume":"13","author":"Ramos","year":"2006","journal-title":"Learn Mem"},{"key":"B13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1586\/14737175.2015.1028370","article-title":"Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents","volume":"15","author":"Rizzo","year":"2015","journal-title":"Expert Rev Neurother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.4088\/JCP.v65n1018","article-title":"Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder","volume":"65","author":"Philipsen","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/JCP.0b013e31819a4bae","article-title":"Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial","volume":"29","author":"Ziegenhorn","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"B16","first-page":"4","article-title":"Comparing the efficacy of medications for ADHD using meta-analysis","volume":"8","author":"Faraone","year":"2006","journal-title":"MedGenMed"},{"key":"B17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00787-012-0286-5","article-title":"Amfetamine and methylphenidate medications for attention-deficit\/hyperactivity disorder: complementary treatment options","volume":"21","author":"Hodgkins","year":"2012","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/archpsyc.56.12.1073","article-title":"A 14-month randomized clinical trial of treatment strategies for attention-deficit\/hyperactivity disorder","volume":"56","author":"Cooperative Group","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-023-00441-6","article-title":"Oppositional defiant disorder","volume":"9","author":"Hawes","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B20","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jaac.2014.05.008","article-title":"Risperidone added to parent training and stimulant medication: effects on attention-deficit\/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression","volume":"53","author":"Gadow","year":"2014","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","article-title":"Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice","volume":"26","author":"De Hert","year":"2011","journal-title":"Eur Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1038\/s41386-018-0039-3","article-title":"A randomized, placebo-controlled trial of extended-release guanfacine in children with autism spectrum disorder and ADHD symptoms: an analysis of secondary outcome measures","volume":"43","author":"Politte","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1176\/appi.ajp.2015.15010055","article-title":"Extended-release guanfacine for hyperactivity in children with autism spectrum disorder","volume":"172","author":"Scahill","year":"2015","journal-title":"Am J Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jaac.2013.11.009","article-title":"Alpha-2 agonists for attention-deficit\/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy","volume":"53","author":"Hirota","year":"2014","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2165\/11537790-000000000-00000","article-title":"Effects of guanfacine extended release on oppositional symptoms in children aged 6\u201312 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial","volume":"24","author":"Connor","year":"2010","journal-title":"CNS Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1177\/10731911221082709","article-title":"The DADYS-screen: development and evaluation of a screening tool for affective dysregulation in children","volume":"30","author":"Otto","year":"2023","journal-title":"Assessment"}],"container-title":["Frontiers in Child and Adolescent Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frcha.2025.1547672\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T06:52:50Z","timestamp":1743144770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frcha.2025.1547672\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":26,"alternative-id":["10.3389\/frcha.2025.1547672"],"URL":"https:\/\/doi.org\/10.3389\/frcha.2025.1547672","relation":{},"ISSN":["2813-4540"],"issn-type":[{"value":"2813-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"article-number":"1547672"}}